Tumor necrosis factor α blockers and the induction of anti-DNA autoantibodies
Open Access
- 1 November 2000
- journal article
- editorial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 43 (11) , 2381-2382
- https://doi.org/10.1002/1529-0131(200011)43:11<2381::aid-anr1>3.0.co;2-m
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trialsArthritis & Rheumatism, 2000
- Antibody Responses to DNA in Normal Immunity and Aberrant ImmunityClinical and Diagnostic Laboratory Immunology, 1998
- Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion ProteinNew England Journal of Medicine, 1997
- Review: Nephritogenic autoantibodies in lupus: Current concepts and continuing controversiesArthritis & Rheumatism, 1996
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- Tumor necrosis factor α in autoimmunity: pretty girl or old witch?Immunology Today, 1992
- Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 miceClinical Immunology and Immunopathology, 1989
- Tumour necrosis factor-α in murine autoimmune 'lupus' nephritisNature, 1988